SLC25A39 and colorectal carcinoma: In addition, C10orf54 and HAVCR2 were mainly expressed in macrophage and monocyte, which indicated that combined knockdown of SLC25A39 in CRC cells and chimeric antigen receptor myeloid-cell immunotherapy targeted to C10orf54 or HAVCR2 might be an effective strategy in CRC immunotherapy.